FINWIRES · TerminalLIVE
FINWIRES

米国株式市場はハイテク、通信、工業株の上昇を背景に高値で取引を終えた。

By

-- 地政学的な緊張が続く中、米国株式市場は木曜日、テクノロジー、通信サービス、工業株主導の幅広い上昇で終値を迎えた。 * CNNによると、ドナルド・トランプ米大統領は木曜日、国防総省当局者からイランに対する最新の軍事選択肢について説明を受ける予定で、これはテヘランに合意を迫るための手段の一つとなる可能性がある。 * ブルームバーグによると、イランの新最高指導者は木曜日、核兵器とミサイル技術を放棄しないと誓い、ホルムズ海峡の支配権を維持する意向を示した。 * 米連邦準備制度理事会(FRB)が重視するインフレ指標である米国のコア個人消費支出(PCE)物価指数は、3月に前年同月比3.2%上昇し、市場予想と一致した。 * 6月限のWTI原油は1バレルあたり1.82ドル下落し、105.06ドルで取引を終えた。一方、国際指標である6月限のブレント原油は3.94ドル下落し、114.09ドルで取引された。・クアルコム(QCOM)の株価は、水曜遅くに発表された第2四半期決算(調整後利益および売上高)が予想を上回ったことを受け、S&P500種指数とナスダック総合指数の中で最大の上げ幅となる約14%上昇した。 ・メタ・プラットフォームズ(META)の株価は、第1四半期決算が予想を上回ったにもかかわらず、2026年の設備投資見通しを前夜に引き上げたことを受け、約8%下落した。

Related Articles

Research

Research Alert: Bio: Q1 Results Above Estimates Despite Meaningful Sales/margin Compression

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BIO delivered Q1 results showing pressure across both segments, with revenue of $592.1M growing 1.1% Y/Y (~$3M above consensus) but declining 4.2% currency neutral. Adjusted EPS of $1.89 fell 25.6% Y/Y yet beat consensus by $0.10, while operating margin deteriorated 420 bps to 6.6% from 10.8% in the prior year. Both Life Science and Clinical Diagnostics segments experienced currency neutral declines due to ongoing academia weakness and Middle East conflicts. Management lowered 2026 guidance, expecting currency neutral revenue of -3.0% to +0.5% growth (down from +0.5% to +1.5%) and operating margin of 10.0%-12.0% (vs. prior 12.0%-12.5%). Despite operational headwinds, BIO maintained strong cash generation with $78.1M in FCF and repurchased ~176K shares. The company's balance sheet remains healthy, with $1.56B in cash and short-term investments, providing financial flexibility amid challenging market conditions, in our view.

$BIO
Asia

ResMed Posts Higher Fiscal Q3 Non-GAAP Earnings, Revenue

ResMed (ASX:RMD) reported Friday fiscal third-quarter non-GAAP earnings of $2.86 per share, up from $2.37 a year earlier.Analysts polled by FactSet expected earnings of $2.80.Revenue for the three months ended March 31 was $1.43 billion, compared with $1.29 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion.The company expects its fiscal 2026 non-GAAP gross margin to be between 62% and 63%.The board declared a quarterly dividend of $0.60 per share, up from $0.53 a year earlier, payable June 18 to shareholders on record as of May 14.

$ASX:RMD
Research

Research Alert: Gddy: Strong Profitability Metrics Offset By Continued Revenue Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:GDDY posted Q1 2026 revenue of $1.2B (+6%), in line with consensus, with EPS of $1.60 beating estimates of $1.52 despite booking deceleration to +2.7% from +5% in Q4. A&C segment growth of +11.6% to $498M showed resilience but continued moderating, while Core Platform remained sluggish at +2.8%. We view booking weakness as concerning given competitive pressures and small business spending constraints that raise questions about growth sustainability. Management reaffirmed 2026 revenue guidance of $5.195B-$5.275B (~6% growth), reflecting limited visibility into booking improvement. However, we see encouraging AI monetization signs with ARPU growth of +9.3% to $246 and Airo AI Builder achieving multi-million dollar annualized bookings within weeks of beta launch. We believe GDDY's impressive margin expansion with NEBITDA margins reaching 32.6% (+210 bps) demonstrates operational discipline, though sustaining A&C growth above 10% remains critical for investor confidence.

$GDDY